341 related articles for article (PubMed ID: 3335018)
21. Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines.
Noordhuis P; Kazemier KM; Kasperrs GJ; Peters GJ
Leuk Res; 1996 Feb; 20(2):127-34. PubMed ID: 8628011
[TBL] [Abstract][Full Text] [Related]
22. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
Riva CM; Rustum YM
Cancer Res; 1985 Dec; 45(12 Pt 1):6244-9. PubMed ID: 2998596
[TBL] [Abstract][Full Text] [Related]
23. Quantitation of resistance of leukemic cells to cytosine arabinoside from BrdUrd/DNA bivariate histograms.
Lacombe F; Belloc F; Dumain P; Puntous M; Lopez F; Bernard P; Boisseau MR; Reiffers J
Cytometry; 1992; 13(7):730-8. PubMed ID: 1451603
[TBL] [Abstract][Full Text] [Related]
24. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
Abe I; Saito S; Hori K; Suzuki M; Sato H
Cancer Res; 1982 Jul; 42(7):2846-51. PubMed ID: 7083175
[TBL] [Abstract][Full Text] [Related]
25. Mechanism of synergistic cell killing by hydroxyurea and cytosine arabinoside.
Tanaka M; Kimura K; Yoshida S
Jpn J Cancer Res; 1985 Aug; 76(8):729-35. PubMed ID: 3930450
[TBL] [Abstract][Full Text] [Related]
26. PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells.
Yang JL; Fernandes DJ; Wheeler KT; Capizzi RL
Int J Radiat Oncol Biol Phys; 1996 Mar; 34(5):1073-9. PubMed ID: 8600090
[TBL] [Abstract][Full Text] [Related]
27. Cellular pharmacology of 1-beta-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells.
Momparler RL; Onetto-Pothier N; Bouffard DY; Momparler LF
Cancer Chemother Pharmacol; 1990; 27(2):141-6. PubMed ID: 2249330
[TBL] [Abstract][Full Text] [Related]
28. Differential modulation of 1-beta-D-arabinofuranosylcytosine metabolism by hydroxyurea in human leukemic cell lines.
Kubota M; Takimoto T; Tanizawa A; Akiyama Y; Mikawa H
Biochem Pharmacol; 1988 May; 37(9):1745-9. PubMed ID: 2454114
[TBL] [Abstract][Full Text] [Related]
29. Variability of 5-bromo-2'-deoxyuridine incorporation into DNA of human glioma cell lines and modulation with fluoropyrimidines.
Mancini WR; Stetson PL; Lawrence TS; Wagner JG; Greenberg HS; Ensminger WD
Cancer Res; 1991 Feb; 51(3):870-4. PubMed ID: 1824826
[TBL] [Abstract][Full Text] [Related]
30. Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia.
Hiddemann W; Kiehl M; Zühlsdorf M; Busemann C; Schleyer E; Wörmann B; Büchner T
Semin Oncol; 1992 Apr; 19(2 Suppl 4):31-7. PubMed ID: 1553573
[TBL] [Abstract][Full Text] [Related]
31. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
[TBL] [Abstract][Full Text] [Related]
32. Biochemical and cytokinetic modulation of L1210 and HL-60 cells by hydroxyurea and effect on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity.
Rauscher F; Cadman E
Cancer Res; 1983 Jun; 43(6):2688-93. PubMed ID: 6189585
[TBL] [Abstract][Full Text] [Related]
33. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
Bhalla K; Nayak R; Grant S
Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
[TBL] [Abstract][Full Text] [Related]
34. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
Seymour JF; Huang P; Plunkett W; Gandhi V
Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
[TBL] [Abstract][Full Text] [Related]
35. Modulation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity in L1210 cells by fluoropyrimidine pretreatment.
Grant S; Cadman E
Cancer Res; 1982 Sep; 42(9):3550-6. PubMed ID: 6213294
[TBL] [Abstract][Full Text] [Related]
36. Role of uridine triphosphate in the phosphorylation of 1-beta-D-arabinofuranosylcytosine by Ehrlich ascites tumor cells.
White JC; Hines LH
Cancer Res; 1987 Apr; 47(7):1820-4. PubMed ID: 3028615
[TBL] [Abstract][Full Text] [Related]
37. Deoxyguanosine enhancement of cytarabine nucleotide accumulation in human leukemia cells.
Akman SA; Ross DD; Joneckis CC; Fox BM; Bachur NR
Cancer Treat Rep; 1985; 69(7-8):851-7. PubMed ID: 4016794
[TBL] [Abstract][Full Text] [Related]
38. Metabolism and toxicity of electroporated 1-beta-D-arabinofuranosylcytosine triphosphate in a human leukemia cell line.
Kubota M; Yorifuji T; Hashimoto H; Shimizu T; Mikawa H
Jpn J Cancer Res; 1990 Dec; 81(12):1314-9. PubMed ID: 2126001
[TBL] [Abstract][Full Text] [Related]
39. Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.
Gandhi V; Plunkett W
Cancer Chemother Pharmacol; 1992; 31(1):11-7. PubMed ID: 1458554
[TBL] [Abstract][Full Text] [Related]
40. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]